BioCentury | Dec 21, 2020
Finance

Dec. 21-23 Financial Quick Takes: Venture rounds for SomaLogic, ONL; plus Jacobio’s HK listing, Cullinan, Gracell and Zhaoke file for IPOs, and more

SomaLogic tops off recent series AProteomics company SomaLogic Inc. added another $81 million to the crossover-heavy series A financing it disclosed in November, bringing the round’s total to $214 million. New investors in the second close...
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...was managing director, head of capital markets, derivatives and risk management at Morgan Stanley.Chinese cancer company Jacobio Pharmaceutical Group Co. Ltd....
...​ Innovent Biologics Inc. eFFECTOR Therapeutics Inc. Nautilus Biotechnology Inc. Epirium Bio Inc. Medeor Therapeutics Inc. BeyondSpring Inc. MaxCyte Inc. Kedrion S.p.A. Kahr Medical Ltd. Jacobio Pharmaceutical Group Co. Ltd....
BioCentury | Oct 2, 2020
Finance

C4 is latest preclinical protein degradation IPO with big aftermarket gain

Public investors again showed their appetite for protein degradation companies Friday, as C4’s upsized IPO was the largest and best-received of three new NASDAQ listings.  Shares of C4 Therapeutics Inc. (NASDAQ:CCCC), a preclinical company based...
Items per page:
1 - 3 of 3
BioCentury | Dec 21, 2020
Finance

Dec. 21-23 Financial Quick Takes: Venture rounds for SomaLogic, ONL; plus Jacobio’s HK listing, Cullinan, Gracell and Zhaoke file for IPOs, and more

SomaLogic tops off recent series AProteomics company SomaLogic Inc. added another $81 million to the crossover-heavy series A financing it disclosed in November, bringing the round’s total to $214 million. New investors in the second close...
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...was managing director, head of capital markets, derivatives and risk management at Morgan Stanley.Chinese cancer company Jacobio Pharmaceutical Group Co. Ltd....
...​ Innovent Biologics Inc. eFFECTOR Therapeutics Inc. Nautilus Biotechnology Inc. Epirium Bio Inc. Medeor Therapeutics Inc. BeyondSpring Inc. MaxCyte Inc. Kedrion S.p.A. Kahr Medical Ltd. Jacobio Pharmaceutical Group Co. Ltd....
BioCentury | Oct 2, 2020
Finance

C4 is latest preclinical protein degradation IPO with big aftermarket gain

Public investors again showed their appetite for protein degradation companies Friday, as C4’s upsized IPO was the largest and best-received of three new NASDAQ listings.  Shares of C4 Therapeutics Inc. (NASDAQ:CCCC), a preclinical company based...
Items per page:
1 - 3 of 3